Research programme: macrocyclic therapeutics - Bristol-Myers Squibb/Ocera Therapeutics
Latest Information Update: 14 Dec 2017
At a glance
- Originator Bristol-Myers Squibb; Tranzyme Pharma
- Developer Bristol-Myers Squibb; Ocera Therapeutics
- Class Macrocyclic compounds; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 11 Dec 2017 Ocera Therapeutics has been acquired by Mallinckrodt
- 04 Sep 2013 No development reported for Undefined indication in USA (PO)
- 15 Jul 2013 Ocera Therapeutics has completed its merger with Tranzyme Pharma